EGFR and breast adenocarcinoma: Presumably this pattern of diminished gemcitabine sensitivity is directly relevant to the anti-neoplastic cytotoxicity detected for gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu] compared to gemcitabine in chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations (Figure.